Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shoulson, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shoulson, I.
NEUROLOGY 1981;31:1333
© 1981 American Academy of Neurology

Huntington disease

Functional Capacities in patients treated with neuroleptic and antidepressant drugs

Ira Shoulson, M.D.

Department of Neurology, University of Rochester Medical Center, Rochester, NY.

To assess the course of Huntington disease (HD) and the efficacy of therapy for chorea and depression, we used a functional evaluation for 22 HD patients who were followed for 13 to 40 months. Functional capacities of all patients declined notwithstanding the modest therapeutic effects of neuroleptic or antidepressant drugs. The quantitative scale seems applicable to long-term studies.

Address correspondence and reprint requests to Dr. Shoulson, Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642.

Accepted for publication February 5, 1981

Work supported by NINCDS Teacher-Investigator Development Award No. 5 K07-NS00397.

Presented in part at the thirty-second annual meeting of the American Academy of Neurology, New Orleans, LA, May 1980.




This article has been cited by other articles:


Home page
 BrainHome page
R. De Diego-Balaguer, M. Couette, G. Dolbeau, A. Durr, K. Youssov, and A.-C. Bachoud-Levi
Striatal degeneration impairs language learning: evidence from Huntington's disease
Brain, November 1, 2008; 131(11): 2870 - 2881.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
M. Teichmann, V. Gaura, J.-F. Demonet, F. Supiot, M. Delliaux, C. Verny, P. Renou, P. Remy, and A.-C. Bachoud-Levi
Language processing within the striatum: evidence from a PET correlation study in Huntington's disease
Brain, April 1, 2008; 131(4): 1046 - 1056.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Runne, A. Kuhn, E. J. Wild, W. Pratyaksha, M. Kristiansen, J. D. Isaacs, E. Regulier, M. Delorenzi, S. J. Tabrizi, and R. Luthi-Carter
Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood
PNAS, September 4, 2007; 104(36): 14424 - 14429.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
M. Teichmann, E. Dupoux, S. Kouider, P. Brugieres, M.-F. Boisse, S. Baudic, P. Cesaro, M. Peschanski, and A.-C. Bachoud-Levi
The role of the striatum in rule application: the model of Huntington's disease at early stage
Brain, May 1, 2005; 128(5): 1155 - 1167.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
M. Mascalchi, F. Lolli, R. D. Nave, C. Tessa, R. Petralli, C. Gavazzi, L. S. Politi, M. Macucci, M. Filippi, and S. Piacentini
Huntington Disease: Volumetric, Diffusion-weighted, and Magnetization Transfer MR Imaging of Brain
Radiology, September 1, 2004; 232(3): 867 - 873.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
V. Gaura, A.-C. Bachoud-Levi, M.-J. Ribeiro, J.-P. Nguyen, V. Frouin, S. Baudic, P. Brugieres, J.-F. Mangin, M.-F. Boisse, S. Palfi, et al.
Striatal neural grafting improves cortical metabolism in Huntington's disease patients
Brain, January 1, 2004; 127(1): 65 - 72.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
R. G. Brown, L. Redondo-Verge, J. R. Chacon, M. L. Lucas, and S. Channon
Dissociation between intentional and incidental sequence learning in Huntington's disease
Brain, November 1, 2001; 124(11): 2188 - 2202.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A.-C. Bachoud-Levi, P. Maison, P. Bartolomeo, M.-F. Boisse, G. Dalla Barba, A.-M. Ergis, S. Baudic, J.-D. Degos, P. Cesaro, and M. Peschanski
Retest effects and cognitive decline in longitudinal follow-up of patients with early HD
Neurology, April 24, 2001; 56(8): 1052 - 1058.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
K. Marder, H. Zhao, R. H. Myers, M. Cudkowicz, E. Kayson, K. Kieburtz, C. Orme, J. Paulsen, J. B. Penney Jr., E. Siemers, et al.
Rate of functional decline in Huntington's disease
Neurology, January 25, 2000; 54(2): 452 - 452.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
B. Kremer, C. M. Clark, E. W. Almqvist, L. A. Raymond, P. Graf, C. Jacova, M. Mezei, M. A. Hardy, B. Snow, W. Martin, et al.
Influence of lamotrigine on progression of early Huntington disease: A randomized clinical trial
Neurology, September 1, 1999; 53(5): 1000 - 1000.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
J P P van Vugt, S Siesling, M Vergeer, E A van der Velde, and R A C Roos
Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study
J. Neurol. Neurosurg. Psychiatry, July 1, 1997; 63(1): 35 - 39.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
M.A. Reveley, S.M. Dursun, and H. Andrews
A comparative trial use of sulpiride and risperidone in Huntington's disease: a pilot study
J Psychopharmacol, January 1, 1996; 10(2): 162 - 165.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by AAN Enterprises, Inc.